5th World Congress of Clinical Lipidology

5th World Congress of Clinical Lipidology is organized by Paragon Global and will be held from Dec 04 - 06, 2026 at The Posthouse Berlin Potsdamer Platz, Berlin, Germany.

Description:
Clinical lipidology continues to play a critical role in the prevention and treatment of cardiovascular disease worldwide. As the understanding of dyslipidemia, lipid metabolism and residual cardiovascular risk rapidly evolves, healthcare professionals require access to the latest evidence, clinical guidelines and therapeutic innovations.

LIPIDS 2026 has been developed to address these challenges by creating an international scientific forum dedicated to lipid disorders, preventive cardiology and metabolic disease. The congress will feature keynote lectures, expert panel discussions, case-based learning, scientific presentations and networking opportunities.

Clinical lipidology is the medical specialty focused on the diagnosis, prevention and treatment of lipid disorders associated with cardiovascular disease risk. This includes conditions such as elevated LDL cholesterol, hypertriglyceridemia, lipoprotein(a) abnormalities and familial hypercholesterolemia.

Modern clinical lipidology integrates preventive cardiology, metabolic medicine and evidence-based lipid management to reduce the burden of atherosclerotic cardiovascular disease (ASCVD), heart attack and stroke.

As cardiovascular disease remains one of the leading causes of mortality globally, advances in lipidology continue to play an increasingly important role in preventive healthcare.

Key Scientific Topics at LIPIDS 2026:
The scientific program at LIPIDS 2026 will cover a wide range of topics in clinical lipidology, dyslipidemia and cardiovascular prevention, including:

• Dyslipidemia and cholesterol management
• Lipoprotein(a) [Lp(a)]
• Apolipoprotein B (ApoB)
• Familial hypercholesterolemia
• Atherosclerosis and ASCVD prevention
• Triglycerides and residual cardiovascular risk
• Preventive cardiology
• Cardiometabolic disease
• Obesity and lipid metabolism
• Diabetes and cardiovascular risk
• Lipidomics and precision medicine
• Emerging lipid-lowering therapies
• PCSK9 inhibitors
• RNA-based lipid therapies
• Inflammation and cardiovascular disease
• Hypertension and metabolic syndrome